|Systematic (IUPAC) name|
|(6aR,10aR) 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl- 6H-Dibenzo(b,d)pyran-9-carboxylic acid|
|Mol. mass||400.551 g/mol|
Ajulemic acid (IP-751) is a synthetic cannabinoid derivative of the non-psychoactive THC metabolite 11-carboxy-THC which shows useful analgesic and anti-inflammatory effects without causing a subjective "high". It is being developed for the treatment of neuropathic pain and inflammatory conditions such as arthritis. It does not however share the anti-emetic effects of other cannabinoids but may be useful for treating pain and chronic inflammatory conditions where nausea is not present. Side effects include dry mouth, tiredness and dizziness. The mechanism of action has not yet been established, but ajulemic acid may activate the CB1 receptor in a different way to psychoactive cannabinoids. 
- ↑ Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life Sciences. 2004 Aug 6;75(12):1513-22.
- ↑ Mitchell VA, Aslan S, Safaei R, Vaughan CW. Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain. Neuroscience Letters. 2005 Jul 15;382(3):231-5.
- ↑ Burstein S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. AAPS Journal. 2005 Jun 29;7(1):E143-8.
- ↑ Vann RE, Cook CD, Martin BR, Wiley JL. Cannabimimetic properties of ajulemic acid. Journal of Pharmacology and Experimental Therapeutics. 2007 Feb;320(2):678-86.
|Plant cannabinoids||CBD • CBDV • CBN • CBG • CBV • CBL • THC • THC-C4 • THCV|
|Cannabinoid metabolites||11-Hydroxy-THC • 11-nor-9-Carboxy-THC|
|Endogenous cannabinoids||Arachidonoyl ethanolamide (Anandamide or AEA) • 2-Arachidonoylglycerol (2-AG) • 2-Arachidonyl glyceryl ether (noladin ether) • Virodhamine • N-arachidonoyl-dopamine (NADA)|
|Synthetic cannabinoid agonists|
|Endocannabinoid activity enhancers|
|Cannabinoid antagonists and inverse agonists|
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies